Almost 4000 women died from cervical cancer in the United States in 2006. Cervical cancer is one of the most common causes of cancer death for American women and certain viral infections are associated with cancer development. Human papillomavirus type 16 (HPV 16) is a high risk type human papillomavirus (HPV) most commonly associated with the squamous cell carcinoma of the cervix. The E6 protein is one of two oncoproteins utilized by HPV 16 for transformation and it works by binding and degrading p53. Researchers have identified a dominant CD8 T cell epitope within the HPV16 E6 protein from a woman who has been able to clear her HPV 16 infection without treatment. T cell were isolated and cultured in vitro. A region within the E6 protein has been identified which contained the dominant epitope. This was followed by the isolation of T cell clones with the specificity to the dominant epitope. These studies were used to define the minimum and optimal amino acid sequence (TIHDIILEC) and the restricting HLA module (HLA-B48). This technology has two potential applications at present: first, immunizing patients with pre-cancerous lesions and second, immunizing patients that have developed cervical cancer. A vaccine that is usable for the majority of the population in fighting pre-cancerous lesions will require the identification of more epitopes that can be combined to form a treatment effective for the general populous. For patients that have fully developed cancer, custom vaccines could be created that have an exact HLA match to the individual. While the therapy has only been tested for HPV 16, a common malignant form, this technology should have some ability to treat some other forms of the virus including those causing warts.